A new hemodynamic index to predict late right failure in patients implanted with last generation centrifugal pump.


Journal

Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809

Informations de publication

Date de publication:
Jul 2021
Historique:
revised: 12 03 2021
received: 15 01 2021
accepted: 28 03 2021
pubmed: 20 4 2021
medline: 11 6 2021
entrez: 19 4 2021
Statut: ppublish

Résumé

Right ventricular failure (RVF) is a severe event that increases perioperative mortality after left ventricle assist device (LVAD) implantation. Right ventricular (RV) function is particularly affected by the LVAD speed by altering RV preload and afterload as well as the position of the interventricular septum. However, there are no studies focusing on the relationship between pump speed optimization and risk factors for the development of late RVF. Between 2015 and 2019, 50 patients received LVAD implantation at San Camillo Hospital in Rome. Of these, 38 who underwent pump speed optimization were included. Post-optimization hemodynamic data were collected. We assessed a new Hemodynamic Index (HI), calculated as follows:  Ten patients had late RVF after LVAD implantation. Five patients required diuretic therapy and speed optimization. Three patients required inotropic support with adrenaline 0.05 μg/kg/min. Two patients needed prolonged continuous venovenous hemofiltration and high dose inotropic support. Multivariate analysis revealed that a low HI (odds ratio 11.5, 95% confidence interval, 1.85-65.5, p [.003]) was an independent risk factor for late RVF after LVAD implantation. We demonstrated a low HI being a significant risk factor for the development of RVF after LVAD implantation. We suggest implementing HI as a decision support tool for goal-direct optimization of the device aiming to reduce the burden of late-onset RVF during the follow-up.

Sections du résumé

BACKGROUND BACKGROUND
Right ventricular failure (RVF) is a severe event that increases perioperative mortality after left ventricle assist device (LVAD) implantation. Right ventricular (RV) function is particularly affected by the LVAD speed by altering RV preload and afterload as well as the position of the interventricular septum. However, there are no studies focusing on the relationship between pump speed optimization and risk factors for the development of late RVF.
METHODS METHODS
Between 2015 and 2019, 50 patients received LVAD implantation at San Camillo Hospital in Rome. Of these, 38 who underwent pump speed optimization were included. Post-optimization hemodynamic data were collected. We assessed a new Hemodynamic Index (HI), calculated as follows: 
RESULTS RESULTS
Ten patients had late RVF after LVAD implantation. Five patients required diuretic therapy and speed optimization. Three patients required inotropic support with adrenaline 0.05 μg/kg/min. Two patients needed prolonged continuous venovenous hemofiltration and high dose inotropic support. Multivariate analysis revealed that a low HI (odds ratio 11.5, 95% confidence interval, 1.85-65.5, p [.003]) was an independent risk factor for late RVF after LVAD implantation.
CONCLUSION CONCLUSIONS
We demonstrated a low HI being a significant risk factor for the development of RVF after LVAD implantation. We suggest implementing HI as a decision support tool for goal-direct optimization of the device aiming to reduce the burden of late-onset RVF during the follow-up.

Identifiants

pubmed: 33870583
doi: 10.1111/jocs.15564
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2355-2364

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTER-MACS (interagency registry for mechanically assisted circulatory support). J Am Coll Cardiol. 2011;57:1890-1898.
Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score: a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163-2172.
Lampert BC, Teuteberg JJ. Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant. 2015;34:1123-1130.
Dang N, Topkara V, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006;25:1-6.
Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139:1316-1324.
Fitzpatrick JR, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27:1286-1292.
Kang G, Ha R, Banerjee D. Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant. 2016;35:67-73.
Uriel N, Sayer G, Addetia K, et al. Hemodynamic ramp tests in patients with left ventricular assist devices. JACC Heart Fail. 2016;4(3):208-217.
Suwa H, Seguchi O, Fujita T, et al. Paracorporeal ventricular assist device as a bridge to transplant candidacy in the era of implantable continuous-flow ventricular assist device. J Artif Organs. 2014;17(1):16-22.
Imamura T, Burkhoff D, Rodgers D, et al. Repeated ramp tests on stable LVAD patients reveal patient-specific hemodynamic fingerprint. ASAIO J. 2017. https://doi.org/10.1097/MAT
Jung MH, Gustafsson F, Houston B, Russell SD. Ramp study hemodynamics, functional capacity, and outcome in heart failure patients with continuous-flow left ventricular assist devices. ASAIO J. 2016;62(4):442-446.
Couperus LE, Delgado V, Khidir MJH, et al. Pump speed optimization in stable patients with a left ventricular assist device. ASAIO J. 2017;63(3):266-272.
Burke MA, Givertz MM. Assessment and management of heart failure after left ventricular assist device implantation. Circulation. 2014;129:1161-1166.
Fitzpatrick JR III, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137:971-977.
Takeda K, Takayama H, Colombo PC. Incidence and clinical significance of late right heart failure during continuous-flow left ventricular assist device support. J Heart Lung Transplant. 2015;34:1024-1032.
Lietz K, Long JW, Kfoury AG, et al. outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497-505.
Topilsky Y, Hasin T, Oh JK, et al. Echocardiographic variables after left ventricular assist device implantation associated with adverse outcome. Circ Cardiovasc Imaging. 2011;4:648-661.
Noor MR, Bowles C, Banner NR. Relationship between pump speed and exercise capacity during HeartMate II left ventricular assist device support: influence of residual left ventricular function. Eur J Heart Fail. 2012;14:613-620.
Jo Mudd, Cuda JD, Halushka M, Soderlund KA, Conte JV, Russell SD. Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. J Heart Lung Transplant. 2008;27:1269-1274.
Pak SW, Uriel N, Takayama H, et al. prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant. 2010;29:1172-1176.

Auteurs

Andrea Montalto (A)

Department of Cardiac Surgery and Heart Transplantation, San Camillo Hospital, Rome, Italy.

Cristiano Amarelli (C)

Department of Cardiac Surgery and Heart Transplant, Monaldi Hospital, Naples, Italy.

Vito Piazza (V)

Division of Cardiology, Department of Cardiac Surgery and Heart Transplantation, San Camillo Hospital, Rome, Italy.

Kali Hopkins (K)

Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Marina Comisso (M)

Department of Cardiac Surgery and Heart Transplantation, San Camillo Hospital, Rome, Italy.

Romina Pantanella (R)

Department of Cardiac Surgery and Heart Transplantation, San Camillo Hospital, Rome, Italy.

Francesco Musumeci (F)

Department of Cardiac Surgery and Heart Transplantation, San Camillo Hospital, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH